🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Gary Altwerger

Yale University

ORCID: 0000-0002-2252-947X

Also affiliated with University of Chicago

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 11 papers. Top paper: “A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability”.

A phase 2 evaluation of pembrolizumab for recurrent Lynch‐like versus sporadic endometrial cancers with microsatellite instability

Cancer(2021)10.1002/cncr.34025

N/A

2.4DataRank · unranked

80 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus MLH-1 methylated characteristics (NCT02899793)

Annals of Oncology(2021)10.1016/j.annonc.2021.04.013

N/A

1.9DataRank · unranked

50 citations

Dana M. Roque, Eric R. Siegel, Natália Buza, Pei Hui, Elena Bonazzoli +28 more

Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Clinical & Experimental Metastasis(2024)10.1007/s10585-024-10297-z

N/A

0.360DataRank · unranked

10 citations

Blair McNamara, Stefania Bellone, Diego Manavella, Cem Demirkiran, Michelle Greenman +16 more

Preclinical Activity of Sacituzumab Govitecan, an Antibody-Drug Conjugate Targeting Trophoblast Cell-Surface Antigen 2 (Trop-2) Linked to the Active Metabolite of Irinotecan (SN-38), in Ovarian Cancer

Frontiers in Oncology(2020)10.3389/fonc.2020.00118

N/A

0DataRank · unranked

64 citations

Salvatore Lopez, Burak Zeybek, Stefania Bellone, Elena Bonazzoli, Silvia Pelligra +17 more

Harnessing the effects of hypoxia-like inhibition on homology-directed DNA repair

Seminars in Cancer Biology(2023)10.1016/j.semcancer.2023.11.007

N/A

0DataRank · unranked

11 citations

Maddie Ghazarian, Peter M. Glazer, Gary Altwerger

In Vivo and In Vitro Efficacy of Trastuzumab Deruxtecan in Uterine Serous Carcinoma

Molecular Cancer Therapeutics(2023)10.1158/1535-7163.mct-23-0126

N/A

0DataRank · unranked

8 citations

Diego Manavella, Stefania Bellone, Blair McNamara, Justin Harold, Dennis Mauricio +17 more

Uterine leiomyosarcomas harboring MAP2K4 gene amplification are sensitive in vivo to PLX8725, a novel MAP2K4 inhibitor

Gynecologic Oncology(2023)10.1016/j.ygyno.2023.03.009

N/A

0DataRank · unranked

4 citations

Justin Harold, Diego Manavella, Stefania Bellone, Levent Mutlu, Tobias M.P. Hartwich +24 more

Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix

Proceedings of the National Academy of Sciences(2024)10.1073/pnas.2321898121

N/A

0DataRank · unranked

18 citations

Kyungjo Jeong, Mari K. Halle, Camilla Krakstad, Blair McNamara, Michelle Greenman +33 more

Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.05.005

N/A

0DataRank · unranked

25 citations

Paola Manara, Diego Manavella, Stefania Bellone, Tobias M.P. Hartwich, Justin Harold +17 more

Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Gynecologic Oncology(2020)10.1016/j.ygyno.2020.06.484

N/A

0DataRank · unranked

4 citations

Stefania Bellone, Luca Zammataro, Barbara Gnutti, Adele Guglielmi, Silvia Pelligra +15 more

Elimusertib (BAY1895344), a novel ATR inhibitor, demonstrates in vivo activity in ATRX mutated models of uterine leiomyosarcoma

Gynecologic Oncology(2022)10.1016/j.ygyno.2022.11.014

N/A

0DataRank · unranked

30 citations

Stefania Bellone, Diego Manavella, Levent Mutlu, Blair McNamara, Tobias M.P. Hartwich +17 more